Correlation of urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG), a biomarker of oxidative DNA damage, and clinical features of hematological disorders: a pilot study.
The 8-hydroxy-2'-deoxyguanosine (8-OHdG), presently the most popular marker for oxidative DNA damage, level has been reported to be elevated in patients with various malignancies. In the present study, urinary 8-OHdG was examined in 44 patients with hematological disorders (13 malignant lymphoma, 11 adult T cell leukemia/lymphoma (ATL), 10 acute leukemia, and 10 myelodysplastic syndrome (MDS)) by an enzyme-linked immunosorbent assay. The pre-therapy level of urinary 8-OHdG in ATL patients was significantly elevated compared with normal controls (25.3+/-12.9 vs. 11.9+/-7.3 ng/mg, P<0.05). Although patients with lymphoma, acute leukemia and MDS also showed higher urinary 8-OHdG levels than normal controls, the differences were not significant. However, two patients with refractory anemia with excess blasts in transformation (RAEB-t) having extreme monocytosis and neutrophilia showed exceptionally high urinary 8-OHdG levels (161.0 and 218.9 ng/mg). Urinary 8-OHdG excretion increased transiently with chemotherapy, and this fluctuation was significant irrespective of the disorder (P<0.05). Interestingly, lymphoma patients with high LDH, advanced stage, poor performance status or International Prognostic Index (IPI) of high/high-intermediate risk had significantly elevated urinary 8-OHdG levels (P<0.05-<0.001). These latter results suggest that urinary 8-OHdG may be a reliable prognostic marker in lymphoma patients and should encourage large scale and long term follow up studies.
Honda
M
M
Department of Hematology, Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki, Japan.
Yamada
Y
Y
Tomonaga
M
M
Ichinose
H
H
Kamihira
S
S
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D004249:DNA Damage; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000652:urine; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006402:Hematologic Diseases / Q000188:drug therapy / Q000652:urine*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D010865:Pilot Projects
D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine